R ev iew A r tic le
I NTRO D U C TIO N
The efficacy of thyroid hormone therapy in hypothyroidism has been known for over a hundred years, since Murray's use of thyroid organotherapy in 1891. This article aims to present evidence for and against these uses and misuses of thyroid hormone therapy.
T y pe s O f Th y ROID h O R m O N e R epl ACem e NT Th e R A py T4 therapy
Synthetic T4 (i.e. L-T4; 3,5,3',5'-tetraiodothyronine) monotherapy is the best standard replacement therapy for patients with hypothyroidism. There is, however, no evidence that T4 treatment is beneficial in cases with suggestive symptoms but normal thyroid function tests. (2) The dose of T4 best relates to lean body mass (1.5-3.0 μg/kg/day), but in routine clinical care, the usual adult dose is 100-150 μg/day. In otherwise healthy adults, an initial dose of 50-100 μg/day can be increased as necessary, after a minimum of four to six weeks (three to five half-lives), in order to obtain a serum thyroid-stimulating hormone (TSH) level of 0.5-2 mU/L. In the presence of ischaemic heart disease or an increased risk of arrhythmias, the TSH target should be increased to < 5 mU/L. This can be achieved by commencing T4 at 25-50 μg/day, and increasing this dose by 25 μg/day after a minimum of four weeks. 
U s e s O f Th y ROID h O R m O N e Th e R A py

Subclinical hypothyroidism
In subclinical hypothyroidism (SCH), the issue regarding the use of thyroid hormone replacement therapy is when, and whether, to intervene. There is general agreement that SCH should be treated during preconception and pregnancy, (4) with the intent to ameliorate the increased risks of miscarriage and foetal loss associated with raised TSH during pregnancy.
Although plausible, (6) the effect of thyroid hormone treatment of SCH on foetal neurocognitive development has not been demonstrated. (7) Usually, if TSH is > 10 mU/L in the presence of SCH, it is generally agreed that treatment is appropriate and likely to be of clinical benefit. (8) However, there is no consensus about the treatment of patients with SCH when TSH is < 10 mU/L.
Although there is evidence of an increased rate of ischaemic heart disease in SCH patients with TSH < 10 mU/L, (9) there are no randomised prospective trials of thyroid hormone therapy that demonstrate benefit. Comorbidities such as dyslipidaemia and ischaemic heart disease, as well as concomitant presence of thyroid peroxidase antibodies (which predicts progression to overt hypothyroidism at about 5% per year (10) ), are factors that prompt the commencement of treatment rather than monitoring alone. The TSH target in the treatment of SCH is the same as that in overt hypothyroidism.
Myxoedema coma
As this condition is very rare, there are no randomised series 
Nontoxic goitre and benign thyroid nodules
Since TSH is the major factor contributing to thyroid growth, it is hypothesised that the suppression of TSH by thyroid hormone will inhibit thyroid growth or even reduce thyroid volume. Studies done on euthyroid patients with multinodular goitre showed a 7%-32% reduction in thyroid volume after one year of TSH suppressive therapy. (14, 15) This is less efficacious than treatment by radioactive iodine therapy. (16) Morever, discontinuation of TSH suppressive therapy leads to thyroid regrowth, (14) and prolonged TSH suppressive therapy has deleterious effects on cardiac and bone health, leading to increased risks of atrial fibrillation and osteoporosis. (17) Hence, thyroid hormone is usually not a recommended therapeutic option in nontoxic goitre or for benign thyroid nodules, especially in elderly patients. It is also contraindicated in patients who have thyroid autonomy, where TSH is already suppressed, as exogenous therapy may result in hyperthyroidism. The only group of patients who will benefit from thyroid hormone therapy are those who develop goitre due to elevated TSH levels, (18) usually as a consequence of Hashimoto's thyroiditis.
Differentiated thyroid carcinoma
TSH suppression reduces the risk of major adverse events occurring during the follow-up of patients with differentiated thyroid carcinoma stage II or higher. (19, 20) Low-risk patients are recommended by the American Thyroid Association (ATA) and the European Thyroid Association (ETA) to have an initial TSH of either 0.1-0.5 mU/L (21) or < 0.1 mU/L (22) , respectively, and a TSH of either 0.3-2 mU/L (21) 
Secondary hypothyroidism
When hypopituitarism is the cause of hypothyroidism, TSH level cannot be used as a target. Instead, a mid-to highnormal free T4 value, regardless of TSH level, is the aim. Dose selection and adjustment frequency are the same as for primary hypothyroidism. Consideration should be given to the adequacy of other pituitary hormonal axes, in particular adrenal function.
T4 replacement can lead to overt borderline hypoadrenalism due to increased steroid hormone clearance, leading to Addisonian crisis. 
Special concerns in pregnancy
m I sU s e O f Th y ROID h O R m O N e Combination T4 and T3 therapy
The combined use of T4 and T3 therapy has been examined in many small trials consisting of patients who were dissatisfied with T4 replacement alone. However, no clear clinical benefit has been identified when adequate blinding was conducted.
Meta-analyses of reported trials have also not identified any benefits of combination T4-T3 therapy. (24) It has been speculated that functional polymorphisms in type 2 iodothyronine deiodinase or thyroid hormone transporters may have a role in the minority of patients who are dissatisfied with T4 monotherapy. (25) A recently published comprehensive review highlights that even though no benefit of combination T4-T3 therapy has been established over T4 therapy monotherapy, methodological issues were present in previous trials, hence the question of the benefit of combination T4-T3 therapy remains unresolved. (26) The review also points out that differences in deiodinase type and activity in different tissues (e.g. between pituitary and other tissues) can result in differential tissue effects. The authors speculate that polymorphisms of deiodinase genes may influence deiodinase bioactivity and intracellular T3 concentrations, thus contributing to differences in individual responses to thyroid hormone therapy, despite similar circulating levels of T4, T3 and TSH. However, evidence against this theory has been published. (27) We suggest that as any putative advantage of combination therapy remains unproven, the administration of combination therapy should not be routine. It should only be considered if symptoms (i.e. 
Use of thyroid gland extract
All thyroid hormone therapies originally used thyroid gland and TSH, since most of the circulating T3 is derived from T4 under normal physiological conditions; and (c) thyroid extract often produces supraphysiological levels of T3, (29) which varies more through the day than if replacement was done using synthetic T4. Therefore, it has been judged that it is easier to provide accurate, stable euthyroidism with synthetic T4 therapy than with thyroid extract, as it avoids both under-, and even subtle, overtreatment. Increasing concern and evidence regarding the potential harm of subclinical hyperthyroidism has also lent support to the use of synthetic T4. Proponents of thyroid extract promote its 'natural' origin and assert that it provides a more effective therapy, especially for the small minority of patients dissatisfied with synthetic T4 therapy due to symptoms of hypothyroidism, because it contains both T4 and T3. Interestingly, the failure of T4 monotherapy to relieve the symptoms attributed to hypothyroidism was also previously raised against thyroid extract. 
Thyroid hormone as a weight loss agent
When used to treat overt hypothyroidism, thyroid hormone therapy promotes weight loss; this is mainly due to diuresis, (33, 34) and fat mass may not change. Changes in thyroid hormone economy occur in obesity (increase in free T3 and TSH, likely mediated by leptin), (35, 36) but do not resemble the changes in hypothyroidism. Short-term weight loss in cases of obesity may be achieved using thyroid hormone therapy, but this includes a significant loss of lean body mass, (37) including cardiac muscle, and an acceleration of the resting heart rate. (38) Thyroid hormone treatment that produces subclinical hyperthyroidism cannot be advocated, as it will increase the risk of arrhythmias, muscle wasting, (39) and possibly bone loss, especially in postmenopausal women. The weight loss effect of thyroid hormone therapy in obesity is modest, inconsistent, and of unproven efficacy and safety in the long term. (40) Thyroid hormone therapy in depression 
remains inconclusive. (48) Some studies show an apparent benefit, but the interpretation of their findings is confounded by suboptimal experimental designs and other interventions such as insulin, glucose, cortisol and vasopressin.
Thyroid hormone therapy in "Wilson's syndrome" and symptomatic euthyroidism
This self-named syndrome is described as the association of common and nonspecific symptoms with normal circulating thyroid hormone levels, with a putative thyroid hormone deficiency requiring therapy using a special form of T3. It has achieved some currency via internet promotion. ATA, however, thoroughly reviewed the literature and found no evidence supporting the existence of this syndrome, (49) which it describes as being inconsistent with known thyroid physiology, having imprecise diagnostic criteria using symptoms that are both nonspecific and prevalent in the normal population, and an incorrect definition of normal body temperature. (50) This problem is most likely a type of functional somatoform syndrome, which should be managed by acknowledging the symptoms and seeking to alleviate them, and not by the spurious use of thyroid hormone, which has not been shown to be helpful.
CO N ClU sIO N
Thyroid hormone therapy using synthetic T4 in overt hypothyroidism, and in specific cases of SCH, is one of the most straightforward, effective and safe therapies in clinical medicine, and is supported by evidence-based reviews. The use of combination T4-T3 therapy, or desiccated thyroid extract is not supported, and the use of thyroid hormone therapy to shrink multinodular goitre or thyroid nodules is only indicated in the presence of an elevated TSH level.
TSH suppression in the treatment of differentiated thyroid carcinoma reduces recurrences in high-risk disease, but is unnecessary in low-risk disease and when follow-up evaluation indicates a low risk of recurrence. Any additional roles for, or variations of, thyroid hormone therapy should be subjected to evaluation by clinical trials rather than be part of routine clinical practice.
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